Clinical trial · Interventional
Effect of Islet Autotransplantation Compared to Oral Antidiabetic Drug.
Effect of Islet Autotransplantation Compared to Oral Antidiabetic Drug in Partially Pancreatectomized Patients Due to Benign Pancreatic Neoplasm.
NCT01922492CI-TRIAL-00019864unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
* Effects of autologous islet transplantation were compared to those of oral anti-diabetic drugs after distal pancreatectomy. * The primary interest is a insulin-secretory function after the surgery in two intervention groups.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Partial Pancreatectomy Due to Benign Pancreatic Neoplasm | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Autologous islet transplantation | Procedure | — | UNRESOLVED |
| Oral anti-diabetic drugs | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Autologous islet transplantation
- description
- Autologous islet transplantation arm: autologous islet transplantation
- interventionNames
- Procedure: Autologous islet transplantation
- type
- ACTIVE_COMPARATOR
- label
- Oral anti-diabetic drugs
- description
- Metformin (starting from 500mg qd with dose adjustment thereafter) with or without vildagliptin (starting from 50mg qd with dose adjustment thereafter)
- interventionNames
- Drug: Oral anti-diabetic drugs
Primary outcomes (1)
- measure
- Changes of insulin secretory function
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who underwent distal pancreatectomy for pathologic diagnosis of pancreatic mass Exclusion Criteria: * Prior history of diabetes mellitus * Patients whose fasting, post-load (75g OGTT) glucose or HbA1c level meet ADA diagnostic criteria * Patients who refused to participate the study
References
Publications (1)
- DERIVEDYoon JW, Jung HS, Jang JY, Kim MJ, Kim JH, Ohn JH, Kim JH, Lee HM, Kim HC, Lee KB, Choi SA, Kim SW, Park KS. Improved Insulin Secretion by Autologous Islet Transplantation, Compared to Oral Antidiabetic Agents, After Distal Pancreatectomy. Cell Transplant. 2015;24(8):1615-26. doi: 10.3727/096368914X682440. Epub 2014 Jun 27. PMID 24978858